Sustainable funding of cell and gene therapies: bluebird bio puts the ball in the payer’s court

By Nader Murad, Associate Consultant Email: nmurad@partners4access.com At JPMorgan’s  37th Healthcare Conference in 2019, bluebird bio provided its strategic outlook and plans for the year where it highlighted its pipeline progress and commercial activities. bluebird’s pipeline consists of several gene therapies which have demonstrated in clinical studies a high likelihood of potentially curing severe rare…

Partners4access to attend BIA’s networking event

As part of its business expansion activities, Partners4Access’ Sophie Schmitz will be attending industry group, BioIndustry Association (BIA)’s Summer Networking Reception on Thursday, July 12. The event will take place at IET Savoy Place, London. P4A became a member of BIA in June this year. BIA represents several stakeholders within the biosciences area from small…

Slow Brexit proceedings frustrates biotech industry

By Aparna Krishnan, Corporate Affairs Lead As the UK Prime Minister’s office is preparing for the cabinet meeting at Chequers this Friday, British businesses including the biotech industry are none the wiser on what lays ahead after March 29, 2019 when the UK exits the European Union. The current discussion is focussed on the Brexit…